Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Ally Bridge Group (NY) LLC
Form 13F · Q2 2026

Ally Bridge Group (NY) LLC

CIK 1822947Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$113M
Reported book value
25
Positions
12
Quarters on record
Top 50
Positions

Ally Bridge Group (NY) LLC — holdings

Top 23 positions of 25, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1NERV Minerva Neurosciences Inc2.2M+31.4%$12M10.7%
2PMN Promis Neurosciences Inc620,319+49.8%$8M7.2%
3TRAX First Tracks Biotherapeutics284,287—$6M5.1%
4AXSM Axsome Therapeutics Inc.16,493—$4M3.6%
5ASMB Assembly Biosciences Inc140,000—$4M3.4%
6WHWK Whitehawk Therapeutics Inc817,939+0.0%$4M3.3%
7EWTX Edgewise Therapeutics Inc83,300−48.3%$3M3.0%
8CLYM Climb Bio Inc249,172—$3M2.9%
9KURA Kura Oncology Inc290,000—$3M2.8%
10CTMX Cytomx Therapeutics Inc.775,000−13.9%$3M2.6%
11AVTX Avalo Therapeutics Inc150,000—$3M2.5%
12PALI Palisade Bio Inc1.2M—$3M2.3%
13SLDB Solid Biosciences Inc255,959−66.6%$3M2.3%
14ANTX An2 Therapeutics Inc526,315+0.0%$3M2.3%
15URGN Urogen Pharma Ltd69,183−65.8%$3M2.3%
16CATX Perspective Therapeutics Inc743,958−19.7%$3M2.2%
17IDYA Ideaya Biosciences Inc67,500—$3M2.2%
18IVA Inventiva Sa634,800−14.8%$2M2.1%
19ALMS Alumis Inc76,459−54.2%$2M1.9%
20OVID Ovid Therapeutics Inc624,561−77.8%$2M1.5%
21EPRX Eupraxia Pharmaceuticals Inc252,175−61.8%$2M1.5%
22IBIO Ibio Inc390,147—$682,7570.6%
23TRAW Traws Pharma Inc786,236—$663,0330.6%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.